What is the recommended dosing regimen for recombinant human growth hormone (hGH) in children, adolescents, and adults with growth hormone deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HGH Dosing Recommendations

For children with growth hormone deficiency, the standard dose is 0.045-0.05 mg/kg/day (equivalent to 28-30 IU/m² per week) by daily subcutaneous injection, with higher doses up to 0.7 mg/kg/week recommended during puberty. For adults with GHD, start with 0.2 mg/day (or 0.006 mg/kg/day if weight-based) and titrate based on IGF-1 levels and clinical response 1, 2.

Pediatric Dosing

Standard Pediatric GHD Dosing

  • Prepubertal children: 0.045-0.05 mg/kg/day (0.3 mg/kg/week divided daily) by subcutaneous injection 1, 2
  • Pubertal patients: Up to 0.7 mg/kg/week divided daily - this higher dose reflects the physiologic increase in GH production during puberty 2, 3
  • Timing: Evening injections recommended to mimic physiological circadian rhythm 1
  • Dose adjustment: Regular intervals based on body weight changes 1

The evidence strongly supports higher dosing during puberty. A randomized multicenter trial demonstrated that pubertal patients receiving 0.7 mg/kg/week achieved 4.6 cm greater near-adult height compared to standard 0.3 mg/kg/week dosing (P < 0.001), without accelerating bone age maturation 3. This dose-response relationship is particularly important for patients who are most growth-retarded at puberty onset.

Condition-Specific Pediatric Dosing

  • Chronic kidney disease: Up to 0.35 mg/kg/week (0.05 mg/kg/day) 1, 2
  • Turner syndrome: Up to 0.375 mg/kg/week divided 3-7 times weekly 2
  • Idiopathic short stature: Up to 0.3 mg/kg/week 2

For CKD patients, meta-analysis showed that 28 IU/m²/week (0.045-0.05 mg/kg/day) produced 1.18 cm/year greater height velocity compared to 14 IU/m²/week, while doubling to 56 IU/m²/week showed no additional benefit 1. This establishes a clear therapeutic ceiling.

Adult Dosing

Two Acceptable Approaches

Non-weight-based (preferred for simplicity):

  • Start: 0.2 mg/day (range 0.15-0.3 mg/day)
  • Titrate: Increase by 0.1-0.2 mg/day every 1-2 months based on IGF-1 levels and clinical response 4, 2

Weight-based:

  • Start: ≤0.006 mg/kg/day
  • Maximum: 0.025 mg/kg/day (age ≤35 years) or 0.0125 mg/kg/day (age >35 years) 4, 2

Critical Dosing Considerations for Adults

Age matters significantly: Older patients (≥60 years) should start at 100-200 μg/day and titrate more slowly due to increased susceptibility to side effects 4. Younger transition patients (<30 years) may require 400-500 μg/day initially 4.

Sex and estrogen status are crucial: Women on oral estrogen require substantially higher GH doses to achieve equivalent IGF-1 levels due to SOCS2-mediated hepatic GH resistance 4. Oral estrogen stimulates a non-competitive post-receptor inhibitor of GH action, suppressing hepatic IGF-1 production. Women switching from oral to transdermal estrogen may need dose reductions 4.

Obesity increases adverse effects: Obese individuals are more prone to side effects when treated with weight-based regimens, warranting lower starting doses 2.

Monitoring and Dose Adjustment

Pediatric Monitoring

  • First year response: Height velocity should increase >2 cm/year over baseline 1
  • IGF-1 levels: Target 0 to +2 SDS (upper half of age-adjusted range commonly used) 5
  • Frequency: Every 3-6 months for growth parameters, more frequently for young patients and advanced CKD 1
  • Non-responders: Assess adherence (measure serum IGF-1), verify weight-adjusted dosing, and address nutritional/metabolic factors before considering treatment failure 1

Adult Monitoring

  • Initial titration: Every 1-2 months during dose adjustment 4, 2
  • Maintenance: Semi-annually with clinical assessment, IGF-1 levels, and adverse effect evaluation 4
  • Target IGF-1: Upper half of age- and gender-adjusted reference range 4
  • Annual labs: Lipid profile and fasting glucose 4

Administration Details

  • Route: Subcutaneous injection only 1, 2
  • Frequency: Daily injections (bioavailability ~80%, T-max 3-6 hours, half-life 2-3 hours) 1
  • Timing: Evening preferred to mimic physiologic secretion 1
  • Rotation: Change injection sites daily (thigh, upper arm, abdomen, buttock) to prevent lipoatrophy 1, 2

Common Pitfalls to Avoid

  1. Underdosing pubertal patients: Failing to increase dose during puberty misses the critical window when physiologic GH production normally surges 3

  2. Ignoring estrogen status in women: Not accounting for oral estrogen's suppressive effect on IGF-1 production leads to inadequate dosing 4

  3. Using excessive doses in older adults: Starting with standard adult doses in patients ≥60 years increases fluid retention and other adverse effects 4

  4. Stopping treatment prematurely: GH should continue until epiphyseal closure in children or until target height achieved 1

  5. Not adjusting for weight changes: Pediatric doses must be recalculated regularly as body weight increases 1

  6. Overlooking non-adherence: Poor response should prompt IGF-1 measurement to verify compliance before declaring treatment failure 1

References

5
Guideline

approach to the patient: case studies in pediatric growth hormone deficiency and their management.

The Journal of clinical endocrinology and metabolism, 2023

Related Questions

How should growth hormone deficiency be diagnosed in patients transitioning from adolescence to adulthood?
What are the diagnostic criteria for growth hormone deficiency in children and adolescents?
Can growth hormone be administered to increase height in a child without growth hormone deficiency?
Does neonatal growth hormone deficiency cause ketosis?
What is the appropriate approach to evaluating and managing a 14-year-old with suspected growth hormone deficiency?
In an adult patient with known metastatic cancer presenting with unilateral arm swelling, what is the appropriate diagnostic and initial management approach?
Does caffeine help tension-type headaches?
Do patients with Hodgkin lymphoma have a higher overall treatment response rate than those with non‑Hodgkin lymphoma?
Can elevated renin levels cause hypokalemia?
At what growth hormone dose do side effects typically appear in adults?
Is it appropriate to transfer a nursing‑home patient with an estimated glomerular filtration rate of 14 mL/min/1.73 m² to the hospital?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.